共 36 条
- [21] Herceptin (H) after adjuvant chemotherapy significantly improves disease-free survival (DFS) in HER2-positive early breast cancer (BC): HERA trial interim analysis EJC SUPPLEMENTS, 2005, 3 (04): : 4 - 4
- [22] Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study ANNALS OF ONCOLOGY, 2020, 31 : S42 - S42
- [28] Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC):: Eastern Cooperative Oncology Group (ECOG) trial E3198. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S125 - S125
- [29] Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
- [30] Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) plus capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)